We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals

56 hedge funds and large institutions have $18.6M invested in Oramed Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

9% more capital invested

Capital invested by funds: $17M → $18.6M (+$1.57M)

1.95% more ownership

Funds ownership: 17.07%19.02% (+1.9%)

2% more funds holding

Funds holding: 5556 (+1)

17% less call options, than puts

Call options by funds: $44K | Put options by funds: $53K

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
56
Holders Change
+1
Holders Change %
+1.82%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
9
Increased
14
Reduced
17
Closed
8
Calls
$44K
Puts
$53K
Net Calls
-$9K
Net Calls Change
-$25K

ORMP Hedge Fund Activity: Q4 2024 in Review

56 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2024, worth a combined $18.6M — up 9.2% from $17M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ORMP positions and 8 closed out — a net gain of 1 holder — while 14 added to existing stakes and 17 trimmed.

The largest buyer was BML Capital Management, adding an estimated $1.09M. The largest seller was Renaissance Technologies, cutting an estimated $222K.

  • 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2024, up from 55 in Q3 2024.
  • Funds reported $18.6M of Oramed Pharmaceuticals stock for Q4 2024, up 9.2% quarter-over-quarter.
  • 9 funds opened new Oramed Pharmaceuticals positions in Q4 2024 and 8 closed out, a net change of +1 holder.
  • The largest Oramed Pharmaceuticals buyer in Q4 2024 was BML Capital Management, an estimated $1.09M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2024 was Renaissance Technologies, an estimated $222K sold.

Based on aggregated 13F filings for Q4 2024.